Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $25.3300 (-1.71%) ($25.0500 - $26.0000) on Tue. Jul. 3, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.74% (three month average) | RSI | 38 | Latest Price | $25.3300(-1.71%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | ADMS declines -2% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Normal for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(22%) IBB(20%) IWO(17%) QQQ(17%) XOP(17%) | Factors Impacting ADMS price | ADMS will decline at least -1.37% in a week (0% probabilities). VIXM(-10%) UNG(-10%) BNDX(-9%) UUP(-8%) VXX(-6%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.37% (StdDev 2.74%) | Hourly BBV | 0 () | Intraday Trend | -2.2% | | | |
|
1 - 5 Day Possible Target | $16.64(-34.31%) | Resistance Level | $26.15 | 5 Day Moving Average | $25.31(0.08%) | 10 Day Moving Average | $25.32(0.04%) | 20 Day Moving Average | $26.15(-3.14%) | To recent high | -22.5% | To recent low | 12% | Market Cap | $716m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |